In vivo selective cancer-tracking gadolinium eradicator as new-generation photodynamic therapy agent

Tao Zhang, Rongfeng Lan, Chi Fai Chan, Ga Lai Law*, Rick W K WONG, Ka-Leung WONG

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)

Abstract

In this work, we demonstrate a modality of photodynamic therapy (PDT) through the design of our truly dual-functional - PDT and imaging - gadolinium complex (Gd-N), which can target cancer cells specifically. In the light of our design, the PDT drug can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species - singlet oxygen - before due excitation. Comprehensive in vitro and in vivo studies had been conducted for the substantiation of the effectiveness of Gd-N as such a tumor-selective PDT photosensitizer. This treatment modality does initiate a new direction in the development of "precision medicine" in line with stem cell and gene therapies as tools in cancer therapy.

Original languageEnglish
Pages (from-to)E5492-E5497
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number51
DOIs
Publication statusPublished - 23 Dec 2014

Scopus Subject Areas

  • General

User-Defined Keywords

  • Gadolinium
  • Imaging
  • In vivo PDT
  • Survivin
  • Tumor recognition

Fingerprint

Dive into the research topics of 'In vivo selective cancer-tracking gadolinium eradicator as new-generation photodynamic therapy agent'. Together they form a unique fingerprint.

Cite this